Intra-Cellular Therapies Announces Positive Topline Results in Second Phase 3 Trial Evaluating Lumateperone as Adjunctive Therapy in Patients with Major Depressive Disorder
June 18, 2024 07:30 ET | Intra-Cellular Therapies Inc.
In Study 502, lumateperone 42 mg achieved statistically significant and clinically meaningful results in both the primary and the key secondary endpoints Lumateperone 42 mg met the primary endpoint...
Grifols completes sale of a 20% equity stake in SRAAS and forges strategic alliance with Haier Group
June 18, 2024 07:30 ET | Grifols, S.A.
With today’s announcement of the transaction completion, Grifols and Haier Group will work together through Shanghai RAAS (SRAAS) to drive synergies that enhance China’s healthcare systemThrough a...
Fourth Quarter and Fiscal Year 2024 Key Operating Metrics
America’s Car-Mart Reports Fourth Quarter and Fiscal Year 2024 Results
June 18, 2024 07:30 ET | America's Car-Mart, Inc.
ROGERS, Ark., June 18, 2024 (GLOBE NEWSWIRE) -- America’s Car-Mart, Inc. (NASDAQ: CRMT) (“we,” “Car-Mart” or the “Company”), today reported financial results for the fourth quarter and full year...
Taysha Gene Therapies Announces Positive Clinical Data Across Adult and Pediatric Patients from Low Dose Cohort in Ongoing REVEAL Phase 1/2 Trials Evaluating TSHA-102 in Rett Syndrome
June 18, 2024 07:30 ET | Taysha Gene Therapies, Inc.
Durable improvements across consistent clinical domains in both adult and pediatric patients, including motor skills, communication/socialization, autonomic function, seizures, and an encouraging...
BB Logo_Tagline_FullColor.png
BridgeBio Pharma Surpasses Interim Analysis Enrollment Target and Receives U.S. FDA Rare Pediatric Disease Designation for BBP-418, a Potential Treatment for Limb-girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9)
June 18, 2024 07:30 ET | BridgeBio Pharma, Inc.
- BridgeBio has surpassed its interim analysis enrollment target for its Phase 3 FORTIFY study of BBP-418 in individuals living with LGMD2I/R9, with top-line results from the interim analysis expected...
Super Hi Reports Unaudited Financial Results for the First Quarter of 2024
SINGAPORE, June 18, 2024 (GLOBE NEWSWIRE) -- Super Hi International Holding Ltd. (NASDAQ: HDL and HKEX: 9658) (“Super Hi” or the “Company”), a leading Chinese cuisine restaurant brand operating...
hennessy VI.jpg
Namib Minerals, an Established African Gold Producer, to Become Publicly Traded Through Business Combination With Hennessy Capital Investment Corp. VI
June 18, 2024 07:30 ET | Hennessy Capital Investment Corp. VI
Namib Minerals is an established African gold producer with an attractive portfolio of mines in Zimbabwe supported by high-grade, low-cost production, extensive infrastructure and pro-mining...
zevra_inline_fullcolor_rgb_12in@300ppi (1).png
Zevra Therapeutics Transitions to Orsini as the Specialty Pharmacy Provider for OLPRUVA® (sodium phenylbutyrate), a Treatment for Certain Urea Cycle Disorders
June 18, 2024 07:30 ET | Zevra Therapeutics
CELEBRATION, Fla. and ELK GROVE VILLAGE, Ill., June 18, 2024 (GLOBE NEWSWIRE) -- Orsini Specialty Pharmacy (Orsini), and Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra) today announced that Orsini...
Altimmune logo.png
Altimmune Announces Oral Presentations of Pemvidutide Clinical Data at Upcoming American Diabetes Association’s Scientific Sessions
June 18, 2024 07:30 ET | Altimmune, Inc
GAITHERSBURG, Md., June 18, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced oral presentations on pemvidutide, an investigational...
Mesa Air Group Logo (black background).png
Mesa Air Group Reports Second Quarter Fiscal 2024 Results
June 18, 2024 07:05 ET | Mesa Air Group, Inc.
PHOENIX, June 18, 2024 (GLOBE NEWSWIRE) -- Mesa Air Group, Inc. (NASDAQ: MESA) (“Mesa” or the “Company”) today reported second quarter fiscal 2024 financial and operating results. Second Quarter...